A comparison of yttrium-90 microsphere radioembolization to hepatic arterial infusional chemotherapy for patients with chemo-refractory hepatic colorectal metastases Journal Article

  

Authors:	Cercek, A.; Gendel, V.; Jabbour, S.; Moore, D.; Chen, C.; Nosher, J.; Capanu, M.; Chou, J. F.; Boucher, T.; Kemeny, N.; Carpizo, D. R.
Article Title:	A comparison of yttrium-90 microsphere radioembolization to hepatic arterial infusional chemotherapy for patients with chemo-refractory hepatic colorectal metastases
Abstract:	Patients with unresectable hepatic colorectal metastases who become chemo-refractory have limited treatment options. Systemic chemotherapies such as TAS102 and regorafenib have been used in the refractory setting, but with only modest improvement in overall survival compared to best supportive care. In patients with liver-only or liver-dominant disease, direct chemotherapy to the liver such as hepatic artery infusional (HAI) chemotherapy and radioembolization (yttrium-90 (Y90)) should be considered. Due to the difficulty of HAI therapy post Y90 for technical reasons, we recommend HAI therapy prior to Y90. © 2017, Springer Science+Business Media New York.
Keywords:	survival; hepatic arterial infusion; refractory; metastatic colorectal cancer; yttrium-90 microsphere radioembolization
Journal Title:	Current Treatment Options in Oncology
Volume:	18
Issue:	7
ISSN:	1527-2729
Publisher:	Springer
Date Published:	2017-07-01
Start Page:	42
Language:	English
DOI:	10.1007/s11864-017-0481-1
PROVIDER:	scopus
PUBMED:	28608276
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85020503641&doi=10.1007%2fs11864-017-0481-1&partnerID=40&md5=94c745d18682f24386339d1826e81192
Notes:	Review -- Export Date: 3 July 2017 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/112459